Investor Stemcell

Michael Marletta Appointed to Governing Board of California’s Stem Cell Agency

iCELL News — Fri, 18 May 2012 18:25:41 +0000

San Francisco, CA –Michael A. Marletta, PhD, President and CEO of The Scripps Research Institute, has been appointed to the Independent Citizens Oversight Committee (ICOC), the governing board of California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM)

“California has led the nation in stem cell research and I’m delighted to be part of an institution that has the potential to change the way we look at and treat disease,” says Dr. Marletta. “Throughout my career my research has focused on the intersection of biology, chemistry and medicine so I hope I will be able to make a valuable contribution to the field of regenerative medicine.”

Dr. Marletta, a renowned biochemist, was named to the ICOC by California State Treasurer Bill Lockyer. He takes one of the seats designated for a representative of a California University under Proposition 71, the voter–approved initiative that created the stem cell agency.

State Treasurer Bill Lockyer said “Dr. Marletta will bring valuable experience and knowledge to the Independent Citizens Oversight Committee and will well serve the people of California as its newest member.”

Dr. Marletta, in addition to being President at CEO at Scripps, is also the Cecil H. and Ida M. Green Professor or Chemistry there. He is a member of the National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine, and is a former recipient of the prestigious MacArthur Fellowship.

“We are fortunate to have someone of Dr. Marletta’s caliber join our board,” says Jonathan Thomas, Chairman of the ICOC. “His scientific background and leadership skills will be invaluable as CIRM begins to move into the next phase of its operations, moving promising candidate therapies from the laboratory into clinical trials in people.”

Profiles are available for all CIRM board members.

About CIRM: CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

You are receiving this email because you opted in at our website.

Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences

iCELL News — Thu, 17 May 2012 22:21:02 +0000

Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences 05/17 09:00 AM

SAN DIEGO, May 17, 2012 /PRNewswire/ — Cardium Therapeutics (CXM:$0.23,00$-0.005,0-2.13%) today announced that Christopher J. Reinhard, Chairman & CEO will present a corporate overview and participate in a Regenerative Medicine Panel being held at the Sachs 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences in West Palm Beach, FLMay 21 – 22, 2012. The Regenerative Medicine Panel, chaired by Bernard Siegel, Executive Director, Genetics Policy Institute and Jeffrey Cohen, Director, Ladenburg Thalmann & Co, Inc., will take place on May 22 at 9:15 a.m. ET and Cardium’s investor presentation is scheduled for 10:40 a.m. ET on the same day in Ballroom B. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) An updated investor presentation is now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. About Cardium Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium’s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen™ topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com. Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. Copyright 2012 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit www.cardiumthx.com. Cardium Therapeutics (CXM:$0.23,00$-0.005,0-2.13%) ™, Generx®,Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate®, Osteorate™, MedPodium®, Appexium®, Linee™, Alena™, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. (CXM:$0.23,00$-0.005,0-2.13%) or Tissue Repair Company. SOURCE Cardium Therapeutics (CXM:$0.23,00$-0.005,0-2.13%)

Get more news on:SYMBOLS: CXMNEWS TYPE: SECTORS: Health Care, Life Sciences Tools and Services, Pharmaceuticals, Health Care Providers and Services

StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial Trial Proceeding to Enroll Patients With Incomplete Injury

iCELL News — Thu, 17 May 2012 22:17:55 +0000

05/17 09:00 AM

NEWARK, Calif., May 17, 2012 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) today announced completion of the first planned interim safety review of the Company’s Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the Company’s proprietary HuCNS-SC® cells (purified human neural stem cells), represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury. A summary of the data will be presented by Armin Curt, M.D., principal investigator for the clinical trial, at the Interdependence 2012Global SCI Conference, which is being held in Vancouver, British Columbia, from May 15 to 17, 2012. The interim data is from the first cohort of patients, all of whom suffered a complete spinal cord injury in which there is no neurological function below the level of the injury. All patients enrolled were transplanted with a dose of 20 million cells at the site of injury in the thoracic spinal cord. There were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first four months following transplantation of the cells. The data from multiple evaluations of the patients during this four month period have been reviewed by an independent Data Safety Monitoring Committee, which has recommended that the study advance to enrollment of patients with incomplete neurological injury. Enrollment is now underway and is open to patients in Europe, the United States and Canada with incomplete spinal cord injury. The trial, which is being conducted at Balgrist University Hospital, Zurich, Switzerland, is the only ongoing clinical trial evaluating neural stem cell transplantation in spinal cord injury. “We are very encouraged by the interim safety outcomes for the first cohort,” said Dr. Curt, who is Professor and Chairman of the Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at Balgrist University Hospital. “The patients in the trial are being closely monitored and undergo frequent clinical examinations, radiological assessments by MRI and sophisticated electrophysiology testing of spinal cord function. The comprehensive battery of tests provides important safety data and is very reassuring as we progress to the next stage of the trial.” The Interdependence 2012 Global SCI Conference is intended to bring together international healthcare and research facilities to showcase their work through presentations, workshops and exhibits and to discuss how to advance research, implement new best practices and shape the next generation of spinal cord injury research. Interdependence 2012 is jointly organized by the Rick Hansen Institute, a Canadian not-for-profit organization committed to accelerating the translation of discoveries and best practices into improved treatments for people with spinal cord injuries, and the Rick Hansen Foundation. About the Spinal Cord Injury Clinical Trial The Phase I/II clinical trial of StemCells, Inc.’s (STEM:$0.80,00$-0.048,0-5.66%) HuCNS-SC® purified human adult neural stem cells is designed to assess both safety and preliminary efficacy. Twelve patients with thoracic (chest-level) neurological injuries at the T2-T11 level are planned for enrollment. The Company has dosed the first three patients all of whom have injuries classified as AIS A, in which there is no neurological function below the injury level. The second and third cohorts will be patients classified as AIS B and AIS C, those with less severe injury, in which there is some preservation of sensory or motor function. The injuries are classified according to the American Spinal Injury Association Impairment Scale (AIS). In addition to assessing safety, the trial will assess preliminary efficacy based on defined clinical endpoints, such as changes in sensation, motor and bowel/bladder function. All patients will receive HuCNS-SC cells through direct transplantation into the spinal cord and will be temporarily immunosuppressed. Patients will be evaluated regularly in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any recovery of neurological function below the injury site. The Company intends to follow the effects of this therapy long-term, and a separate four-year observational study will be initiated at the conclusion of this trial. The trial is being conducted at Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation, and is open for enrollment to patients in Europe, Canada and the United States. If you believe you may qualify and are interested in participating in the study, please contact the study nurse either by phone at +41 44 386 39 01 or by email at stemcells.pz@balgrist.ch. Additional information about the Company’s spinal cord injury program can be found on the StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) website at http://www.stemcellsinc.com/Therapeutic-Programs/Clinical-Trials.htm and at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm, including video interviews with Company executives and independent collaborators. About Balgrist University Hospital Balgrist University Hospital, University of Zurich is recognized worldwide as a highly specialized center of excellence providing examination, treatment and rehabilitation opportunities to patients with serious musculoskeletal conditions. The clinic owes its leading international reputation to its unique combination of specialized medical services. The hospital’s carefully-balanced, interdisciplinary network brings together under one roof medical specialties including orthopedics, paraplegiology, radiology, anesthesiology, rheumatology, and physical medicine. More information about Balgrist University Hospital is available at www.balgrist.ch. About StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company’s lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The Company recently reported results from a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. The trial results showed preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has received authorization from the FDA to initiate a Phase I/II clinical trial in dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer’s disease. StemCells (STEM:$0.80,00$-0.048,0-5.66%) also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells (STEM:$0.80,00$-0.048,0-5.66%) is available at http://www.stemcellsinc.com. The StemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014 Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of retaining continued authorization to conduct a clinical trial in Switzerland in chronic spinal cord injury; the prospect for screening and then enrolling patients into the AIS B and AIS C cohorts; the prospect for evaluating trial patients for changes in their sensation, motor and bowel/bladder function; the potential of the Company’s HuCNS-SC cells to treat spinal cord injury and other central nervous system disorders; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company’s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company’s HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in PMD, spinal cord injury or in future clinical trials of proposed therapies for other diseases or conditions given the novel and unproven nature of the Company’s technologies; uncertainties regarding the ability of preclinical research, including research in animal models, to accurately predict success or failure in clinical trials; uncertainties regarding the Company’s ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company’s ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company’s cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company’s ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and in its subsequent reports on Form 10-Q and Form 8-K. CONTACT: Rodney YoungStemCells, Inc. (STEM:$0.80,00$-0.048,0-5.66%) Chief Financial Officer (510) 456-4128

Ian StoneRusso Partners (619) 308-6541 Image: company logo

Get more news on:SYMBOLS: STEMNEWS TYPE: SECTORS: Health Care, Health Care Equipment and Supplies, Pharmaceuticals, Health Care Providers and Services

World’s First Approved Stem Cell Drug Approved:Osiris Therapeutics Inc.

iCELL News — Thu, 17 May 2012 21:33:37 +0000

World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal Historic decision offers hope to children suffering from life-threatening GvHD 05/17 04:36 PM

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics Inc. (OSIR:$5.26,00$-0.05,00-0.94%) announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. The historic decision marks the world’s first regulatory approval of a manufactured stem cell product and the first therapy approved for GvHD — a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis. “I am very proud of the leadership role Canada has taken in advancing stem cell therapy and particularly gratified that this historic decision benefits children who would otherwise have little hope,” said Andrew Daly, M.D., Clinical Associate Professor, Department of Medicine and Oncology at the University of Calgary, Canada and Principal Investigator in the phase 3 clinical program for Prochymal. “As a result of Health Canada’s comprehensive review, physicians now have an off-the-shelf stem cell therapy in their arsenal to fight GvHD. Much like the introduction of antibiotics in the late 1920′s, with stem cells we have now officially taken the first step into this new paradigm of medicine.” Prochymal was authorized under Health Canada’s Notice of Compliance with conditions (NOC/c) pathway, which provides access to therapeutic products that address unmet medical conditions and which have demonstrated a favorable risk/benefit profile in clinical trials. Under the NOC/c pathway, the sponsor must agree to carry out confirmatory clinical testing. “Today is not only a great day for Osiris, but for everyone involved in the responsible development of stem cell therapies,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. “Most importantly, today is a great day for children and their families who bravely face this horrific disease. While today marks the first approval of a stem cell drug, now that the door has been opened, it will surely not be the last.” Health Canada’s authorization was made following the recommendation of an independent expert advisory panel, commissioned to evaluate Prochymal’s safety and efficacy. In Canada, Prochymal is now authorized for the management of acute GvHD in children who fail to respond to steroids. The approval was based on the results from clinical studies evaluating Prochymal in patients with severe refractory acute GvHD. Prochymal demonstrated a clinically meaningful response at 28 days post initiation of therapy in 61-64 percent of patients treated. Furthermore, treatment with Prochymal resulted in a statistically significant improvement in survival when compared to a historical control population of pediatric patients with refractory GvHD (p=0.028). The survival benefit was most pronounced in patients with the most severe forms of GvHD. As a condition of approval, the clinical benefit of Prochymal will be further evaluated in a case matched confirmatory trial and all patients receiving Prochymal will be encouraged to participate in a registry that will monitor the long-term effects of the therapy. “Refractory GvHD is not just deadly to the patients it afflicts, but is devastating for the family, friends, and caregivers who watch helplessly as the disease progresses,” said Joanne Kurtzberg, MD, Head of the Pediatric Bone Marrow Transplant Program at Duke University and Lead Investigator for Prochymal. “I have personally seen Prochymal reverse the debilitating effects of severe GvHD in many of my patients and now, after nearly two decades of research, the data demonstrating consistently high response rates, a strong safety profile and improved survival clearly support the use of Prochymal in the management of refractory GvHD.” Prochymal is currently available in several countries, including the United States, under an Expanded Access Program (EAP). Prochymal will be commercially available in Canada later this year. “Today Osiris turns the promise of stem cell research into reality, delivering on decades of medical and scientific research,” said Peter Friedli, Chairman and Co-founder of Osiris. “It took 20 years of hard work and perseverance and I want to personally thank everyone involved for their dedication to this important mission.” In addition to the extensive intellectual property protection Osiris has around Prochymal, which includes 48 issued patents, Health Canada’s decision will also provide Prochymal with regulatory exclusivity within the territory. Canada affords eight years of exclusivity to Innovative Drugs such as Prochymal, and an additional six-month extension is available since it addresses a pediatric population. Webcast and Conference Call A webcast and conference call is scheduled for tomorrow, May 18, 2012 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company’s website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants). A replay of the conference call will be available approximately two hours after the completion of the call through May 24, 2012. Callers can access the replay by dialing (855) 859-2056 (U.S. participants) or (404) 537-3406 (international participants). The audio replay confirmation code is 82905846. To access a replay of the webcast, visit the Investor Relations section of the company’s website at http://investor.osiris.com/events.cfm. About GvHD GvHD represents a major unmet medical need with no approved treatment until Prochymal. GvHD is the leading cause of transplant related mortality, in which immune cells contained within the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. Severe GvHD can cause blistering of the skin, intestinal hemorrhage and liver failure. Severe GvHD is extremely painful and fatal in up to 80 percent of cases. Currently, steroids are used as first-line therapy with a success rate of only 30-50 percent. When steroids fail, treatment options are limited to immunosuppressive agents used off-label with little benefit and significant toxicities. About Prochymal (remestemcel-L) Prochymal is the world’s first approved drug which has a stem cell as its active ingredient. Developed by Osiris Therapeutics (OSIR:$5.26,00$-0.05,00-0.94%) , Prochymal is an intravenous formulation of mesenchymal stem cells (MSCs), which are derived from the bone marrow of healthy adult donors between the ages of 18 and 30 years. The MSCs are selected from the bone marrow and grown in culture so that up to 10,000 doses of Prochymal can be produced from a single donor. Prochymal is truly an off-the-shelf stem cell product that is stored frozen at the point-of-care and infused through a simple intravenous line without the need to type or immunosuppress the recipient. Prochymal is currently approved in Canada for the management of acute graft-versus-host disease (GvHD) in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program. Prochymal is currently in Phase 3 trials for refractory Crohn’s disease and also being evaluated in clinical trials for the treatment of myocardial infarction (heart attack) and type 1 diabetes. About Notice of Compliance with Conditions An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. Products approved under Health Canada’s NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. Such products have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to such products on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame. About Osiris Therapeutics (OSIR:$5.26,00$-0.05,00-0.94%) Osiris Therapeutics, Inc. (OSIR:$5.26,00$-0.05,00-0.94%) is the leading stem cell company, having developed the world’s first approved stem cell drug, Prochymal. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic areas and wound healing areas. Osiris currently markets Prochymal for refractory GvHD, Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. The company’s pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology, including 48 U.S. and 144 foreign patents. Osiris, Prochymal, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. (OSIR:$5.26,00$-0.05,00-0.94%) More information can be found on the company’s website, www.Osiris.com. (OSIR-G) Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the following: our product development efforts; our clinical trials and anticipated regulatory requirements and the ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for Prochymal, Chondrogen and our other MSC and biologic drug candidates; our cash needs; patents and proprietary rights; the safety and ability of our potential products to treat disease and the results of our scientific research; our plans for sales and marketing; our plans regarding our facilities; types of regulatory frameworks we expect will be applicable to our potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events. Source: Osiris Therapeutics, Inc. (OSIR:$5.26,00$-0.05,00-0.94%)

Get more news on:SYMBOLS: OSIRNEWS TYPE: SECTORS: Health Care, Pharmaceuticals, Health Care Providers and Services

Osiris Therapeutics’ Stem Cell Drug, Prochymal, Receives Marketing Clearance from Health Canada

iCELL News — Thu, 17 May 2012 21:01:04 +0000

Osiris Therapeutics’ Stem Cell Drug, Prochymal, Receives Marketing Clearance from Health Canada 05/17 04:56 PM

04:56 PM EDT, 05/17/2012 ( — Osiris Therapeutics (OSIR:$5.26,00$-0.05,00-0.94%) has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease (GvHD) in children. GvHD is a complication of bone marrow transplantation. The approval marks the first time a manufactured stem cell product has been given regulatory clearance and the first therapy approved for GvHD. Shares are up 4.56% to $5.50 in the after hours session, with a 52-week range of $4.12 – $8.39. Price: 5.50, Change: +0.24, Percent Change: +4.56

Cellerant Announces Publication Demonstrating Significant Survival Benefits and Preclinical Proof of Concept

iCELL News — Mon, 14 May 2012 20:10:32 +0000

Cellerant Announces Publication Demonstrating Significant Survival Benefits and Preclinical Proof of Concept With Myeloid Progenitors as Radiation Countermeasure

SAN CARLOS, Calif., May 14, 2012 (BUSINESS WIRE) — Cellerant Therapeutics, Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the publication of a radiation countermeasure study demonstrating that cryopreserved, allogeneic mouse myeloid progenitor cells significantly improved survival in mice irradiated with lethal doses of radiation. The study, published on May 4, 2012 in the scientific journal, Radiation Research, represents the first report of an effective radiation countermeasure for Acute Radiation Syndrome (ARS) across a broad range of lethal radiation doses when administered as late as seven (7) days after irradiation. These results show that myeloid progenitor cells are one of the most promising radiation countermeasures among all therapeutics currently under development with respect to efficacy, timing and practicality of administration.

The work was carried out in collaboration with scientists at the Armed Forces Radiobiology Research Institute (AFRRI) and is entitled “Myeloid Progenitors: A Radiation Countermeasure that is Effective when Initiated Days after Irradiation” which appears online ahead of print on the website http://www.rrjournal.org/doi/abs/10.1667/RR2894.1?journalCode=rare .

The publication describes the use of Cellerant’s cryopreserved, allogeneic myeloid progenitor cells developed in mice to elucidate its potential as a radiomitigator against lethal doses of ionizing radiation in various strains of mice. Pooled allogeneic myeloid progenitor cells were transfused into unmatched recipients irradiated with lethal doses of ionizing radiation known to cause ARS in hematopoietic tissues. Survival benefit was dose dependent and significant even when administration of the product was delayed up to seven (7) days post-irradiation. The ability to delay the administration of a radiomitigator by 24 to 48 hours is critical to allow for the time it takes disaster teams to respond to radiation victims in an emergency situation.

“These study results exceed our expectations of the potential survival benefits of myeloid progenitor cells,” said Ram Mandalam, President and CEO of Cellerant. “We are excited about the data as it represents demonstration of proof of concept for our CLT-008 — human myeloid progenitor therapy as a radiation medical countermeasure. We continue to work closely with AFFRI in performing further studies and with the government in advancing our product closer to approval for therapeutic use.”

Cellerant is developing CLT-008, human myeloid progenitor cells, for the treatment of ARS under a United States Government contract awarded on September 1, 2010 and valued up to $170 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services.

In ARS applications, CLT-008 is intended to provide hematopoietic cellular support after exposure to ionizing radiation from a nuclear weapon or from a nuclear accident. Cellerant has conducted various preclinical studies to evaluate whether a single administration of myeloid progenitor cells has the potential to provide effective treatment for ARS in an emergency situation when administered up to seven days post-exposure to radiation. CLT-008 is being developed under the U.S. Food and Drug Administration’s Animal Rule for ARS. This approval pathway is available when human efficacy studies are neither ethical nor feasible and requires demonstration of efficacy in representative and well-characterized animal models along with safety and pharmacokinetic testing in human clinical trials. There is currently no FDA-approved medical countermeasure to treat ARS. If licensed by the FDA, the federal government could purchase CLT-008 for the Strategic National Stockpile under Project Bioshield. Project Bioshield is designed to accelerate the research, development, purchase and availability of effective medical countermeasures for the Strategic National Stockpile.

About CLT-008

CLT-008 is a unique, off-the-shelf, cryopreserved, cell-based therapy that contains human Myeloid Progenitor Cells derived from adult hematopoietic stem cells that have the ability to mature into functional granulocytes, platelets and red blood cells in vivo. In preclinical models, CLT-008 has been shown to be highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival with a high degree of efficacy. Cellerant is developing CLT-008 as an effective treatment for chemotherapy-induced neutropenia, protection following exposure to acute radiation, and facilitating engraftment of cord blood transplantation.

CLT-008 is currently in a Phase 1 study in patients undergoing cord blood transplants for the treatment of hematological malignancies. CLT-008 is intended to rapidly produce neutrophils and platelets in vivo and facilitate long-term engraftment in patients undergoing bone marrow or cord blood transplantation. A second Phase I/II study is evaluating CLT-008 in acute leukemia patients with chemotherapy-induced neutropenia. CLT-008 may shorten the time to neutrophil recovery and decrease the risks of febrile neutropenia and infection.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.

For more information, visit: http://www.cellerant.com .

SOURCE: Cellerant Therapeutics, Inc.

        Cellerant Therapeutics Inc.
        Jun Yoon, 650-232-2122
        Executive Director, Corporate Development
        info@cellerant.com

New York Stem Cell Foundation scientist grows bone from human embryonic stem cells

iCELL News — Mon, 14 May 2012 20:05:30 +0000

NEW YORK, NY (May 14, 2012) — Dr. Darja Marolt, an Investigator at The New York Stem Cell Foundation (NYSCF) Laboratory, is lead author on a study showing that human embryonic stem cells can be used to grow bone tissue grafts for use in research and potential therapeutic application. Dr. Marolt conducted this research as a post-doctoral NYSCF – Druckenmiller Fellow at Columbia University in the laboratory of Dr. Gordana Vunjak-Novakovic.

The study is the first example of using bone cell progenitors derived from human embryonic stem cells to grow compact bone tissue in quantities large enough to repair centimeter-sized defects. When implanted in mice and studied over time, the implanted bone tissue supported blood vessel ingrowth, and continued development of normal bone structure, without demonstrating any incidence of tumor growth.

Dr. Marolt’s work is a significant step forward in using pluripotent stem cells to repair and replace bone tissue in patients. Bone replacement therapies are relevant in treating patients with a variety of conditions, including wounded military personnel, patients with birth defects, or patients who have suffered other traumatic injury.

Since conducting this work as proof of principle at Columbia University, Dr. Marolt has continued to build upon this research as an Investigator in the NYSCF Laboratory, developing bone grafts from induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem cells in that they can also give rise to nearly any type of cell in the body, but iPS cells are produced from adult cells and as such are individualized to each patient. By using iPS cells rather than embryonic stem cells to engineer tissue, Dr. Marolt hopes to develop personalized bone grafts that will avoid immune rejection and other implant complications.

###

The New York Stem Cell Foundation has supported Dr. Marolt’s research throughout her career, first through a NYSCF – Druckenmiller Fellowship to fund her post-doctoral work at Columbia University, and now with a NYSCF – Helmsley Investigator Award at The New York Stem Cell Foundation Laboratory. “The continuity of funding provided by NYSCF has allowed me to continue my research uninterrupted, making progress more quickly than would have otherwise been possible,” Dr. Marolt said.

The New York Stem Cell Foundation (NYSCF) conducts cutting-edge translational stem cell research in its laboratory in New York City and supports research by stem cell scientists at other leading institutions around the world. More information is available at www.nyscf.org.

[ Print | E-mail | Share ] [ Close Window ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

HOME DISCLAIMER PRIVACY POLICY TERMS & CONDITIONS CONTACT US TOP
Copyright ©2012 by AAAS, the science society.

Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives

iCELL News — Mon, 14 May 2012 20:03:53 +0000

Funding Will Support Research, Development, and Availability of Next Generation Non-Surgical Stem Cell Treatments

By Regenerative Sciences, Inc.

Regenerative Sciences, Inc.

Last modified: 2012-05-14T13:29:18Z

Published: Monday, May. 14, 2012 – 6:29 am

DENVER, May 14, 2012 — /PRNewswire/ — Regenerative Sciences, Inc., a company dedicated to advancing orthopedic care through non-surgical adult stem cell procedures, today announced that it has secured a $2M investment from philanthropist, visionary and businessman John C. Malone, PhD, chairman of Liberty Media Corporation. In addition to advancing Regenerative Sciences’ clinical and lab-based stem cell research, the investment will help support the national expansion of their Regenexx™ Physician Network.

Regenerative Sciences’ Regenexx procedures utilize a patient’s own stem cells to help repair a broad range of common injuries and degenerative conditions, including cartilage lesions, torn ligaments and tendons, osteoarthritis and bulging spinal discs. For many, the procedures offer a viable alternative to arthroscopic surgery, open-joint surgery, or joint replacement surgery. Regenexx patients experience little or no downtime from the procedures and avoid the lengthy rehabilitation period associated with most surgical procedures.

“We are proud of our accomplishments in the field of regenerative interventional orthopedics and it’s exciting that our work has drawn the attention of such a noted entrepreneur and philanthropist,” said Christopher J. Centeno, M.D., Chief Executive Officer of Regenerative Sciences. “Dr. Malone shares our vision for forging the next generation of minimally invasive regenerative treatments. This investment will not only bolster our existing stem cell research programs and make our procedures available in all regions of the U.S., but it will help us maintain a leadership role in clarifying the regulatory space for physician stem cell use.”

Regenerative Sciences is at the forefront of regenerative orthopedic medicine within the United States and the company is bringing the future of orthopedic treatments to patient care today.

About Regenerative Sciences

Regenerative Sciences is an outgrowth of the Centeno-Schultz clinic, where we are reinventing orthopedic care for the 21st century using key biologics such as stem cells, next generation tools and devices, and unique therapeutic approaches. Our signature initiative, Interventional Orthopedics, allows doctors to treat orthopedic conditions through injection, rather than traditional invasive surgery. The Regenexx Physician Network brings together like-minded physicians from around the country to offer more patients access to our innovative procedures. For more information on Regenerative Sciences and Regenexx procedures, visit: www.regenexx.com

About John C. Malone, PhD

Dr. John C. Malone holds a bachelor’s degree in electrical engineering and economics from Yale University, where he was a Phi Beta Kappa and merit scholar. He also holds a master’s degree in industrial management and a Ph.D. in operations research from Johns Hopkins University.

Dr. Malone is Chairman of Liberty Media Corporation, a position he has held since 1990. Dr. Malone is also the Chairman of the Board of Liberty Global, Inc. (LGI), a position he has held since June, 2005. From 1996 to March 1999 when Tele-Communications, Inc. (TCI) merged with AT&T Corp., he was also Chairman and Chief Executive Officer of TCI. Previous to that, from 1973 to 1996, Dr. Malone served as President and CEO of TCI. He currently serves on the Board of Directors for CATO Institute, Expedia, Inc., Discovery Communications, Inc., and SiriusXM.

Contact:

Dave Klein Klein New Media mediainquiries@kleinnewmedia.com Phone (303) 800-6467

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Regenerative Sciences, Inc.

Read more here: http://www.sacbee.com/2012/05/14/4488299/regenerative-sciences-receives.html#storylink=cpy

BioTime HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells

iCELL News — Mon, 14 May 2012 18:07:14 +0000

HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease 05/14 08:45 AM

ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (BTX:$3.78,00$0.04,001.07%) announced today the publication of a scientific paper demonstrating the effectiveness of HyStem®-C in the transplantation of heart muscle-derived cells in an animal model of heart disease. The paper, “Functional performance of human cardiosphere-derived cells delivered in an in situ polymerizable hyaluronan-gelatin hydrogel,” is published online (ahead of print) in the peer-reviewed journal Biomaterials. The report demonstrates that the survival of human heart-derived cells is markedly improved when the cells are formulated in HyStem®-C, a product being developed by BioTime (BTX:$3.78,00$0.04,001.07%) under the trade name ReneviaTM as a cell delivery device. In today’s publication, human heart-derived cells were transplanted into the hearts of mice around the time of injury in an animal heart attack model. When transplanted without matrix, the heart cells fared poorly, as is commonly observed in the absence of such support. However, when the cells were transplanted with HyStem®-C there was a significant increase in the number of surviving transplanted cells. Another significant finding reported in the study is that transplantation of the cells with HyStem®-C into the injured heart muscle resulted in an increase in left ventricular ejection fraction (LVEF), a measure of the ability of the cells to restore strength to the damaged heart wall. The lead author on the paper is Ke Cheng of the Cedars-Sinai Heart Institute in Los Angeles, California. Other authors from Cedars-Sinai are Deliang Shen, Baiming Sun, Giselle Galang, and Eduardo Marbán. Authors from Capricor, Inc. of Los Angeles, California are Agnieszka Blusztajn, Rachel R. Smith, and Linda Marbán. Additional authors are Tao-Sheng Li from the Department of Stem Cell Biology at Nagasaki University Graduate School of Biomedical Science in Nagasaki, Japan; Glenn D. Prestwich from the Department of Medicinal Chemistry and Center for Therapeutic Biomaterials at the University of Utah in Salt Lake City; and BioTime (BTX:$3.78,00$0.04,001.07%) author Thomas I. Zarembinski. “Heart disease remains the number one cause of mortality in the United States,” said William Tew, Ph.D., BioTime’s Chief Commercial Officer. “We are gratified to see the utility of our HyStem® technology in the field of cardiology as it has been previously reported in neurology and orthopedics. We see the development of these unique matrices as a strategic means of capturing near-term commercial opportunities while building a foundation for a large pipeline of transplantable human cells derived from pluripotent stem cells such as human embryonic stem and induced pluripotent stem cells.” BioTime’s goal is to obtain approval to market Renevia™ in European Union countries by the end of 2013 for use in the transplantation of adipose tissue for reconstructive and dermatological surgery. A discussion of this use of ReneviaTM in a presentation by Dr. Tew, which also describes BioTime’s other plans for its HyStem® line of products, is available online at www.biotimeinc.com. Background BioTime (BTX:$3.78,00$0.04,001.07%) is a leader in developing, manufacturing, and marketing proprietary biocompatible hydrogels that mimic the human extracellular matrix (ECM). The human ECM is a web of molecules surrounding cells that is essential to the formation, function, and growth of discrete tissues and organs in the body. BioTime’s (BTX:$3.78,00$0.04,001.07%) HyStem® hydrogels support the growth and directed differentiation of stem cells by mimicking the ECM, and are designed as injectable, resorbable matrices for tissue engineering, regenerative medicine, and for research applications involving the laboratory culture of human cells. Uses of BioTime’s (BTX:$3.78,00$0.04,001.07%) HyStem® technology has been reported on in over 90 scholarly publications and is presently being used at several leading medical institutions investigating potential cell-based therapies for osteoarthritis, myocardial infarction, stroke, brain tumors, and wound healing. HyStem® offers a convenient delivery matrix and its in situ polymerization creates a biocompatible, resorbable scaffold for cell proliferation and tissue regeneration. About BioTime, Inc (BTX:$3.78,00$0.04,001.07%) BioTime (BTX:$3.78,00$0.04,001.07%) , headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime (BTX:$3.78,00$0.04,001.07%) develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate™ cell lines, HyStem® hydrogels, culture media, and differentiation kits. BioTime (BTX:$3.78,00$0.04,001.07%) is developing Renevia™ (formerly known as HyStem®-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. As an injectable product, Renevia™ may address an immediate need in cosmetic and reconstructive surgeries and other procedures by improving the process of transplanting adipose derived cells, mesenchymal stem cells, or other adult stem cells. BioTime’s (BTX:$3.78,00$0.04,001.07%) wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research. BioTime’s (BTX:$3.78,00$0.04,001.07%) therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime’s (BTX:$3.78,00$0.04,001.07%) majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. Cell Cure’s minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure’s OpRegen™ retinal cell product for use in the treatment of age-related macular degeneration. BioTime’s (BTX:$3.78,00$0.04,001.07%) subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples, and therapeutic strategies using vascular progenitor cells engineered to destroy malignant tumors. ReCyte Therapeutics, Inc. is developing applications of BioTime’s (BTX:$3.78,00$0.04,001.07%) proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime’s (BTX:$3.78,00$0.04,001.07%) newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime’s (BTX:$3.78,00$0.04,001.07%) research products. In addition to its stem cell products, BioTime (BTX:$3.78,00$0.04,001.07%) develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s (BTX:$3.78,00$0.04,001.07%) lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional information about BioTime (BTX:$3.78,00$0.04,001.07%) , ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at www.biotimeinc.com. Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime (BTX:$3.78,00$0.04,001.07%) and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime (BTX:$3.78,00$0.04,001.07%) and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s (BTX:$3.78,00$0.04,001.07%) Securities and Exchange Commission filings. BioTime (BTX:$3.78,00$0.04,001.07%) disclaims any intent or obligation to update these forward-looking statements. To receive ongoing BioTime (BTX:$3.78,00$0.04,001.07%) corporate communications, please click on the following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts Source: BioTime, Inc. (BTX:$3.78,00$0.04,001.07%)

Get more news on:SYMBOLS: BTXNEWS TYPE: SECTORS: Health Care, Health Care Equipment and Supplies, Pharmaceuticals, Industrials, Electrical Equipment, Information Technology, Electronic Equipment and Instruments

Fibrocell Science Submits a Phase II Study Protocol to the FDA

iCELL News — Mon, 14 May 2012 17:32:33 +0000

Fibrocell Science Submits a Phase II Study Protocol to the FDA to Evaluate the Use of azficel-T in Treating Restrictive Burn Scars 05/14 09:00 AM

EXTON, Pa.–(BUSINESS WIRE)– Fibrocell Science, Inc. (FCSC:$0.30,00$-0.05,00-14.29%) announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company’s Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell’s lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn scars. “Submitting the study protocol to the FDA is an important step towards evaluating a new potential therapeutic use for azficel-T, recently approved by the FDA for the treatment of nasolabial fold wrinkles,” said Fibrocell’s Chairman and CEO David Pernock. “Azficel-T is being studied to assess its potential for addressing an unmet need in the treatment of patients suffering with restrictive burn scars.” About Fibrocell Science, Inc. (FCSC:$0.30,00$-0.05,00-14.29%) Fibrocell Science, Inc. (FCSC:$0.30,00$-0.05,00-14.29%) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science (FCSC:$0.30,00$-0.05,00-14.29%) is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com. Forward-Looking Statements All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC. Source: Fibrocell Science, Inc. (FCSC:$0.30,00$-0.05,00-14.29%)

Get more news on:SYMBOLS: FCSCNEWS TYPE: Top News, Top Stories: InvestingSECTORS: Health Care, Pharmaceuticals